腹腔大动脉动脉瘤的治疗策略:全面的系统性审查
Egle Kavaliunaite1,2, Joachim Sejr Skovbo Kristensen2,3, Sissel Scheurer4
1Cardiovascular and Renal Research Unit, Institute for Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark.
Journal of cardiovascular development and disease
|December 24, 2025
概括
像他类药物和ARBs这样的重用药物在动物模型中显示出减少腹腔大动脉瘤 (AAA) 大小的前景. 然而,研究质量和标准化对于将这些发现转化为人类临床试验至关重要.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 翻译医学是一种翻译医学.
背景情况:
- 腹腔大动脉瘤 (AAA) 是一种严重的疾病,缺乏有效的药理疗法.
- 动物模型被用于研究AAA病理生理学和药物疗效,但临床翻译具有挑战性.
研究的目的:
- 系统地审查在动物模型中评估的重用药物对AAA进展的影响.
- 为了确定药物类别与AAA潜在的治疗益处.
主要方法:
- 对14127篇文章的系统审查,包括144项研究,遵守PRISMA指南.
- 按解剖治疗化学 (ATC) 代码分类的药物,并对动物模型中AAA直径的影响进行评估.
主要成果:
- 心血管,代谢和免疫调节剂 (例如,他类药物,ARBs,甲胺,拉巴胺素) 表明动脉瘤直径减少.
- 研究模型,治疗时间和方法限制 (例如缺乏盲目) 中观察到显著的异质性.
- 潜在的出版偏见可能会影响积极发现的占主导地位.
结论:
- 在AAA启动后显示有效性的药物可能具有最有前途的临床效果.
- 标准化,高质量的临床前研究对于推进人类试验的AAA药物开发至关重要.
相关概念视频
Aneurysm III: Interprofessional Care
235
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
235
Aneurysm II: Clinical Manifestations and Diagnostic Studies
193
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
193
Aneurysm IV: Nursing Management
350
Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
350
Aortic Regurgitation III: Medical Management
366
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
366
Peripheral Artery Disease III: Interprofessional Care
217
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
217
Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291


